Covidien (NYSE: COV)
COV (?Covidien?) previously reported that the Company?s Tri-Staple technology platform has achieved more than $1 Billion in product sales since launching in mid-2010.
COV (?Covidien?) Tri-Staple technology platform for endoscopic surgical stapling is the first-of-its-kind technology that enables surgeons to use staplers in a broader range of tissue thicknesses than ever before. Surgeons have rapidly adopted and use Tri-Staple technology reloads across surgical specialties including bariatric, thoracic, colorectal, general, hepatobiliary and gynecological surgery. Endo GIA Reloads with Tri-Staple technology are sold in more than 45 countries.
The benefits delivered by Tri-Staple technology are achieved due to its graduated compression design and progressive staple heights, which provide less stress on tissue during compression and clamping1, the potential for greater perfusion into the staple line2 and the ability to manage tissue variability.
Covidien (NYSE: COV) is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
In my opinion this is a stock to watch!
(Read Full Disclaimer at http://crweselect.com/disclaimer)
Related Articles - Covidien, NYSE: COV,
|
Email this Article to a Friend!
Receive Articles like this one direct to your email box! |
